- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Monheim, October 6, 2016 – Bayer plans to further expand its position in the market for biological crop protection products and has invested some EUR 16 million in new capacity for research, development and production at its Wismar site.
“As a global, innovation-driven Life Science company, we have not only set ourselves ambitious growth targets,” stressed Dr. Mathias Kremer, Head of Strategy and Portfolio Management at the Crop Science Division, to approximately 100 guests at the inauguration ceremony on October 6. “The capacity expansion at the Wismar site is also an important step in offering farmers around the world new solutions for modern, sustainable agriculture. The use of biologicals is becoming increasingly important in this context.”
“The integrated site at Wismar will play a major part in our growth plans,” added Daniel Karsch, Managing Director of Bayer CropScience Biologics GmbH. “We have created ideal conditions in Wismar to ensure that our scientists and experts can work together successfully in the fermentation and production of natural fungi.”
Taking part in the event were Ralf Svoboda, Head of the Technology Section in the Ministry of Economics, Construction and Tourism of the State of Mecklenburg-West Pomerania; Thomas Beyer, Mayor of the Hanseatic City of Wismar; representatives of the participating construction and service companies; members of the communities near the site; and Bayer’s employees at the Wismar site. Wismar is part of the company’s global R&D network and an important production site for biologicals. Bayer employs a total of some 45 people at the site.
Natural fungi activities concentrated in Wismar
Bayer has concentrated its research and development activities on natural fungi in Wismar. At the disposal of the company’s researchers is an approximately 1,600 m2, two-story building complex comprising laboratories, technical centers and offices.
The newly built production facility meets all product quality and safety standards. With an area of more than 4,000 m2, the facility offers enough space for optimal production conditions. As a result, Bayer is well equipped for the future and can react flexibly to new market conditions.
BioAct™ and Contans™: biologicals to control nematodes and fungal diseases
The first biological product – Contans™ WG against sclerotinia rot – was approved in Germany in 1997. It was the first time that marketing authorization had been granted for a biological fungicide in Germany. Bayer develops, produces and markets biological products for integrated crop protection. The products are primarily substances based on living microorganisms such as bacteria and fungi, or on natural substances.
Biologicals have an outstanding environmental profile and are one of the four cornerstones of integrated crop solutions at Bayer, along with improved seeds, chemical crop protection products and supporting services. Various formulations of the fungicide Contans™ WG and the nematicide BioAct™ are produced in Wismar. BioAct™ is used mainly in fruit and vegetable growing in a broad range of countries.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.